Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01208155 · ClinicalTrials.gov registry record · Phase 1

Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT01208155 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01208155, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

Study in healthy males to assess bioavailability of 4 different fostamatinib tablets

Interventions

  • DRUG Fostamatinib

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-09
Est. Completion 2010-11
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT01208155

The ClinicalTrials.gov registry entry for NCT01208155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Fostamatinib is the first listed.

NCT01208155 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01208155 about?

NCT01208155 is a clinical study titled "Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets". Study in healthy males to assess bioavailability of 4 different fostamatinib tablets

What is the current status of trial NCT01208155?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-09. Estimated completion is 2010-11.

What interventions are being tested in trial NCT01208155?

The interventions under investigation include: Fostamatinib (DRUG).

Who is sponsoring clinical trial NCT01208155?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.